Magle Group today announces that the publication of its Annual Report for the financial year 2025 will be postponed.
The Annual Report, originally scheduled for publication on 30 April 2026, is now expected to be published on 9 June 2026. The delay is due to the ongoing audit process, which requires additional time to be completed.
Magle Group remains committed to ensuring the accuracy and completeness of its financial reporting and considers the extension necessary to finalize the audit in accordance with applicable standards.
Contacts Aaron
Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com
Redeye Nordic Growth AB is the company's Certified Adviser.
Attachments
Magle Group Announces Change in Publication Date for Annual Report 2025
© Modular Finance, source Nordic Press Releases